Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Many variations on this as combo therapy of chk1 and Pd-1 of great importance ... to a deal both development of the CHK1 inhibitor and Wee1 inhibitor were halted? This at the time when GSK pushed ...

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ETTo highlight differentiated drug discovery capabilities with its Generative ...

ACR-368, a CHK1/2 inhibitor, is Acrivon’s most advanced ... Acrivon’s second clinical-stage asset, ACR-2316, is a dual WEE1/PKMYT1 inhibitor that has been progressing ahead of schedule.

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 ... selective WEE1/PKMYT1 inhibitor designed ...

ACR-368, specifically targeting CHK1/2i, and ACR-2316, aimed at WEE1/ PKMYT1i, are central to Acrivon’s pipeline and are being closely watched by investors and analysts alike for their potential ...

CHK1 also phosphorylates and activates WEE1 during G2 (centriole maturation), which can phosphorylate and inhibit CDK1 activity. CDK1/Cyclin B interacts with Aurora kinase A to enhance its ...

ACR-368, a CHK1/2 inhibitor, is Acrivon’s most advanced clinical asset ... Acrivon’s second clinical-stage asset, ACR-2316, is a dual WEE1/PKMYT1 inhibitor that has been progressing ahead of schedule.